A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

Trial Details

NCT ID
NCT05927571
Phase
PHASE1
Sponsor
Genentech, Inc.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Cevostamab
  • Elranatamab
  • Tocilizumab
Locations (sample)
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • Waratah, New South Wales, Australia|-32.90667,151.72647
  • Adelaide, South Australia, Australia|-34.92866,138.59863
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Prahan, Victoria, Australia

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Diagnosis of R/R MM per IMWG criteria
  • For female participants of childbearing potential: agreement to remain abstinent or use contraception
  • For male participants: agreement to remain abstinent or use a condom

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →